PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11853879-8	2002	Conversely, prolonged treatment of B16 cells with DFMO stimulated tyr activity by a posttranslational mechanism, probably requiring polyamine depletion.	Eflornithine	50-54	tyrosinase	Mus musculus	66-69	
11853879-9	2002	Combination treatment with alphaMSH and DFMO synergistically activated tyr.	Eflornithine	40-44	tyrosinase	Mus musculus	71-74	
3928149-6	1985	Administration of different doses of DFMO in drinking water to B16 melanoma tumor bearing mice also resulted in an increase in tyrosinase activity and a dose dependent inhibition (86-90%) of tumor growth.	Eflornithine	37-41	tyrosinase	Mus musculus	127-137	
3919940-2	1985	The stimulation of tyrosinase (EC 1.10.3.1) activity and melanin formation by DFMO was closely associated with intracellular depletion of putrescine and spermidine developed in response to the drug.	Eflornithine	78-82	tyrosinase	Mus musculus	19-29	
3924051-0	1985	Potentiation by alpha-difluoromethylornithine of the activity of 3,4-dihydroxybenzylamine, a tyrosinase-dependent melanolytic agent, against B16 melanoma.	Eflornithine	16-45	tyrosinase	Mus musculus	93-103	
3924051-1	1985	Continuous exposure for 96 hr of B16 melanoma cells in culture to 2.5 mM alpha-difluoromethylornithine (DFMO), a specific and irreversible inhibitor of ornithine decarboxylase, resulted in a marked increase in the activity of the enzyme tyrosinase, and also 20% cell kill as assessed by clonogenic assay.	Eflornithine	73-102	tyrosinase	Mus musculus	237-247	
3924051-4	1985	This observed cytotoxicity with the combination suggests that induction of tyrosinase by DFMO sensitizes B16 melanoma cells to the melanolytic activity of DHBA.	Eflornithine	89-93	tyrosinase	Mus musculus	75-85	
3924051-5	1985	Oral administration of DFMO to mice bearing subcutaneous B16 melanomas also resulted in marked increases in the activity of tyrosinase in the tumor tissue.	Eflornithine	23-27	tyrosinase	Mus musculus	124-134